The Dermatological Drugs Market: 2017 – 2030 - Opportunities, Challenges, Strategies & Forecasts​


Release Date: July 2017
Number of Pages: 337
Number of Tables and Figures: 46

Synopsis: With an aging world population and rising expectations about skin, hair, and nail appearance, the prevalence of some of the most common skin disorders continues to rise. With the exception of Melanoma, most skin disorders are not life threatening. However, they can have serious effects on daily life by causing visible physical damage, embarrassment, and social and occupational restrictions.

Although surgery and other therapies are widely used for the treatment of certain skin conditions, dermatological drugs continue to account for the highest percentage of spending within the wider market for dermatology products.
Expected to reach nearly $25 Billion in global spending by the end of 2017, dermatological drugs remain the preferred approach to treat common skin disorders, ranging from Acne to more complicated conditions such as Psoriasis. Despite the loss of patent protection for several blockbuster drugs which has attracted generic competition, the market is ripe for future growth with a number of novel drugs in late-stage development.
The “Dermatological Drugs Market: 2017 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the dermatological drugs ecosystem including dermatological disorders, application areas, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for dermatological drugs from 2017 through to 2030. The forecasts are segmented for over 7 therapeutic categories, 5 regions and 25 leading countries.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.
For a Sample and Table of Contents please contact info@snsintel.com

Pricing: The report is available for the following price: 

Single User License: USD 2,500

Company Wide License (Single Site): USD 3,500

Company Wide License (Global Site): USD 6,500

Key Findings:
The report has the following key findings:
  • Expected to reach nearly $25 Billion in global spending by the end of 2017, dermatological drugs remain the preferred approach to treat common skin disorders, ranging from Acne to more complicated conditions such as Psoriasis.
  • Biologics are continuing to retain their strong foothold in the dermatological drugs market with a number of recent approvals such as Bavencio (Avelumab), Dupixent (Dupilumab) and Siliq (Brodalumab).
  • New drug development programs for Psoriasis and Atopic Dermatitis are largely based on selective inhibition of interleukins including IL-4, IL-5, IL-12, IL-13, IL-17, IL-23 and IL-31.
  • Other programs include but are not limited to PD-L1 (Programmed Death Ligand-1) antibodies; topical treatments such as JAK (Janus Kinase) inhibitors, TYIs (Tyrosine Kinase Inhibitors) and PDE-4 (Phosphodiesterase-4) inhibitors; MEK and BRAF inhibitors; and new classes of antibiotics.
  • The market is continuing to consolidate with several prominent acquisitions such as Pfizer's takeover of dermatology specialist Anacor Pharmaceuticals, in a deal valued at $5.2 Billion.

Topics Covered:
The report covers the following topics:
  • Dermatological drugs ecosystem
  • Market drivers and barriers
  • Dermatological disorders, application areas and key trends
  • Analysis of key drug classes and leading dermatological drugs
  • Future drug development pipeline
  • Dermatological drug delivery technologies
  • Industry roadmap and value chain
  • Profiles and strategies of over 90 leading ecosystem players, including dermatological drug developers
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2017 till 2030

Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
  • Therapeutic Category
    • Acne & Rosacea
    • Alopecia & Hair Disorders
    • Dermatitis
    • Psoriasis
    • Skin Infections
    • Skin Cancer
    • Other Conditions
  • Regional Markets
    • ​Asia Pacific
    • Europe
    • Middle East & Africa
    • North America
    • Latin & Central America
  • Country Markets
    • ​Brazil
    • Canada
    • China
    • Egypt
    • France
    • Germany
    • Greece
    • India
    • Israel
    • Italy
    • Japan
    • Mexico
    • Netherlands
    • Poland
    • Portugal
    • Russia
    • Saudi Arabia
    • South Africa
    • South Korea
    • Spain
    • Switzerland
    • Taiwan
    • Turkey
    • UK
    • USA

Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the dermatological drugs opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2020 and at what rate will it grow?
  • Which countries and submarkets will see the highest percentage of growth?
  • What are the prospects of biosimilar drugs in dermatology?
  • How big is the market for Psoriasis drugs?
  • Who are the key market players and what are their strategies?
  • How will patent expirations of innovator drugs impact the market?
  • What strategies should dermatological drug manufacturers adopt to remain competitive? 

List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:
AB Science
Abbot Laboratories
AbbVie
AbGenomics International
Aclaris Therapeutics
Actelion Pharmaceuticals
Alder Biopharmaceuticals
Allergan
Almirall
Amgen
Amryt Pharma
Anacor Pharmaceuticals
ApoPharma
Apotex
Aralez Pharmaceuticals
Arbor Pharmaceuticals
Array BioPharma
Astellas Pharma
AstraZeneca
Basilea Pharmaceutica
Bayer
BioAlliance Pharma 
Biocon
Biofrontera
Biogen
Biotest
BMS (Bristol-Myers Squibb)
Boehringer Ingelheim
Cadila Pharmaceuticals
Can-Fite BioPharma
Celgene Corporation
Celltrion Healthcare
Chugai Pharmaceuticals
Cipher Pharmaceuticals
Cubist Pharmaceuticals 
Depomed
Dermavant Sciences
Dermira
Dr. Reddy's Laboratories
Eli Lilly and Company
EPI Group
EPI Health
Exelixis
Exicure
FAES Farma
Fibrocell Science
Forward-Pharma
G&E Herbal Biotechnology
Galapagos
Galderma
Genentech
Glenmark Pharmaceuticals
GSK (GlaxoSmithKline)
Horizon Pharma
Hospira
Hoth Therapeutics
Idera Pharmaceuticals
Immune Pharmaceuticals
Incyte Corporation
Innovation Pharmaceuticals
Janssen Biotech 
Johnson & Johnson
JT (Japan Tobacco)
Kadmon Holdings
Kythera Biopharmaceuticals
LEO Pharma
Lipidor
Maruho Company
Mayne Pharma Group
Meda Pharmaceuticals
Melinta Therapeutics
Merck & Co.
Merck KGaA
Momenta Pharmaceuticals
MorphoSys
Mylan
Nestle Skin Health
Novan
Novartis
Ono Pharmaceutical Company
Onxeo
Paratek Pharmaceuticals
Patagonia Pharmaceuticals
Pfizer
PharmaDerm
Photocure
Pierre Fabre (Laboratoires Pierre Fabre)
Pola Pharma
Poli Group
Promius Pharma
Provectus Biopharmaceuticals
Purdue Pharma
Reata Pharmaceuticals
Regeneron Pharmaceuticals
Roche Holding (F. Hoffmann-La Roche)
Roivant Sciences
Samsung Bioepis
Samsung BioLogics
Samsung Group
Sandoz
Sanofi
Sienna Biopharmaceuticals
Sinclair Pharma
Sirbal
Stiefel Laboratories
Sun Pharma (Sun Pharmaceutical Industries)
Takeda Pharmaceutical Company
Teva Pharmaceutical Industries
The Medicines Company
Theravance Biopharma
ThermiGen
Topotarget
Torii Pharmaceutical Company
U.S. FDA (Food and Drug Administration)
UCB
University of Pennsylvania
Valeant Pharmaceuticals International
Vitaeris
XenoPort
Zydus Group (Cadila Healthcare)